The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Elevated invasive potential of glioblastoma stem cells
Open accessAbstract
Glioblastomas (GBMs) are the most lethal and common types of primary brain tumors. The hallmark of GBMs is their highly infiltrative nature. The cellular and molecular mechanisms underlying the aggressive cancer invasion in GBMs are poorly understood. GBM displays remarkable cellular heterogeneity and hierarchy containing self-renewing glioblastoma stem cells (GSCs). Whether GSCs are more invasive than non-stem tumor cells and contribute to the invasive phenotype in GBMs has not been determined. Here we provide experimental evidence supporting that GSCs derived from GBM surgical specimens or xenograts display greater invasive potential in vitro and in vivo than matched non-stem tumor cells. Furthermore, we identified several invasion-associated proteins that were differentially expressed in GSCs relative to non-stem tumor cells. One of such proteins is L1CAM, a cell surface molecule shown to be critical to maintain GSC tumorigenic potential in our previous study. Immunohistochemical staining showed that L1CAM is highly expressed in a population of cancer cells in the invasive fronts of primary GBMs. Collectively, these data demonstrate the invasive nature of GSCs, suggesting that disrupting GSCs through a specific target such as L1CAM may reduce GBM cancer invasion and tumor recurrence.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Radiotherapy Plus Concomitant and Adjuvant Temozolomide for Glioblastoma
Stupp, R., Mason, W. P., van den Bent, M. J., Weller, M., Fisher, B., Taphoorn, M. J. B., Belanger, K., Brandes, A. A., Marosi, C., Bogdahn, U., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043330 · Cited by 21,807
Hypoxia-inducible factors regulate tumorigenic capacity of glioma stem cells
Li, Z., Bao, S., Wu, Q., Wang, H., Eyler, C., Sathornsumetee, S., Shi, Q., Cao, Y., Lathia, J., McLendon, R. E., et al. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.03.018 · Cited by 1,354
Self-citationTargeting Cancer Stem Cells through L1CAM Suppresses Glioma Growth
Bao, S., Wu, Q., Li, Z., Sathornsumetee, S., Wang, H., McLendon, R. E., Hjelmeland, A. B., & Rich, J. N. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-1079 · Cited by 427
Self-citation
Cited by
Diffuse Glioma Heterogeneity and Its Therapeutic Implications
Nicholson, J. G., & Fine, H. A. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1474 · Cited by 460
Glioblastoma Stem Cells: Driving Resilience through Chaos
Prager, B. C., Bhargava, S., Mahadev, V., Hubert, C. G., & Rich, J. N. (2020) · Trends in Cancer · doi:10.1016/j.trecan.2020.01.009 · Cited by 401
Self-citationThe ZEB1 pathway links glioblastoma initiation, invasion and chemoresistance
Siebzehnrubl, F. A., Silver, D. J., Tugertimur, B., Deleyrolle, L. P., Siebzehnrubl, D., Sarkisian, M. R., Devers, K. G., Yachnis, A. T., Kupper, M. D., Neal, D., et al. (2013) · EMBO Molecular Medicine · doi:10.1002/emmm.201302827 · Cited by 381
The role of glioma stem cells in chemotherapy resistance and glioblastoma multiforme recurrence
Auffinger, B., Spencer, D., Pytel, P., Ahmed, A. U., & Lesniak, M. S. (2015) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.2015.1051968 · Cited by 292
Shan, Z.-N., Tian, R., Zhang, M., Gui, Z.-H., Wu, J., Ding, M., Zhou, X.-F., & He, J. (2016) · Oncotarget · doi:10.18632/oncotarget.12385 · Cited by 59
Glioblastoma modeling with 3D organoids: progress and challenges
Wang, X., Sun, Y., Zhang, D. Y., Ming, G.-L., & Song, H. (2023) · Oxford Open Neuroscience · doi:10.1093/oons/kvad008 · Cited by 46
Metadata
- Authors
- Cheng, L., Wu, Q., Guryanova, O. A., Huang, Z., Huang, Q., Rich, J. N., & Bao, S.
- Venue
- Biochemical and Biophysical Research Communications
- Publisher
- Elsevier BV
- Published
- 2011-03
- Volume
- 406
- Issue
- 4
- Pages
- 643-648
- ISSN
- 0006-291X (ISSN-L)
- OpenAlex
- W1971046933
- Cited by
- 199
- References
- 3
- FWCI
- 6.21
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.